UNSPSC 51392226: Metizoline hydrochloride

This classification denotes an adrenergic agonist with the molecular formula C13H14N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PU364U720Z, chemically known as 4,5-dihydro-2-((2-methylbenzo(b)thien-3-yl)methyl)-1h-imidazole monohydrochloride but more generally known as metizoline hydrochloride, which bears US NIH Compound Identifier 68629. Most nations, for tariff and trade purposes, schedule metizoline hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, METIZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Metizoline hydrochloride bears US NLM identifiers UMLS ID C2983811 and NCI Concept Code C90632. SMILES: CC1C(C2CCCCC2S1)CC3=NCCN3.CL.

UNSPSC 51392226 Metizoline hydrochloride is a Commodity code that covers pharmaceutical products; however, the recent state and local opportunities tagged under this code show a mismatch with the nominal scope. The Seminole County, Florida IFB solicits Naloxone (an opioid antagonist used in overdose response) and drug deactivation systems, while the Texas Health and Human Services Commission RFI concerns direct-to-manufacturer pharmacy benefit contracting strategy — neither addresses metizoline hydrochloride specifically. The code shows minimal relevant recent activity aligned with its pharmaceutical substance name, suggesting either sparse procurement demand for metizoline itself or inconsistent UNSPSC tagging in state and local systems.

Issuing bodies engaging with this code include county health departments (Seminole County) and state health and human services agencies (Texas HHS Commission), indicating health-sector buyers rather than a broad cross-section of local governments. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) represents direct pharmaceutical procurement tied to community health initiatives, while the Texas RFI (HHS0017013, posted April 3, 2026) signals state-level pharmacy benefit program redesign activity. Geographic activity is concentrated in the South — Florida and Texas appear in the recent record — with no evidence of activity in other states. The narrowness of the opportunity set and the disconnect between the code's pharmaceutical name and actual solicitations suggest this is either a low-activity code or one experiencing inconsistent classification by state procurement offices.